《新股消息》美中嘉和(02453.HK)今起招股 一手入場費3,313元
中國腫瘤醫療服務提供商美中嘉和(02453.HK)公布招股詳情,擬全球發售3,942.02萬股H股,香港公開發售佔一成,國際發售佔九成。每股招股價介乎14.1至16.4元。每手200股計,一手入場費3,313.08元。該股今日(今年12月29日)起招股,下周四(明年1月4日)中午截止,預期約於明年1月9日掛牌。聯席保薦人為中金及海通國際。
以招股價中位數15.25元計,公司上市料淨集資約5.03億元,當中約59.4%擬用於償還部分計息銀行貸款,即為廣州醫院一期建設提供資金的計息銀行貸款本金,本金額為5億元人民幣;約30.6%用於為上海醫院的籌建提供資金,預計其將於2026年1月開始營運;約10%用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.